The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...

Russian forces have attacked the village of Antonivka in Kherson Oblast, injuring a 35-year-old woman. Source: Kherson Oblast ...

Coronary artery calcium (CAC) scores have become a non-invasive way for physicians to easily determine how much plaque has built up inside a patient's coronary arteries, but the question has been how ...

A treatment need not meet certain criteria for efficacy to qualify an employee for FMLA leave, an agency official wrote in an ...

Trump Suggests Use of Emergency Powers and the Military for Deportations Donald Trump addressed his plans for mass deportations in a social media post. He is expected to interview candidates for ...

A view of the new Beijing Stock Exchange at the Financial Street, in Beijing, China, November 15, 2021. REUTERS/Tingshu Wang/File Photo Asian stocks rose on Tuesday while U.S. bond yields and the ...